Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Gsk (GLAXF) Invested Capital (2016 - 2025)

Historic Invested Capital for Gsk (GLAXF) over the last 17 years, with Q2 2025 value amounting to $1.8 billion.

  • Gsk's Invested Capital changed N/A to $1.8 billion in Q2 2025 from the same period last year, while for Jun 2025 it was $1.8 billion, marking a year-over-year change of. This contributed to the annual value of $63.7 billion for FY2024, which is 126.6% up from last year.
  • According to the latest figures from Q2 2025, Gsk's Invested Capital is $1.8 billion.
  • In the past 5 years, Gsk's Invested Capital ranged from a high of $64.0 billion in Q4 2024 and a low of $1.8 billion during Q2 2025
  • For the 5-year period, Gsk's Invested Capital averaged around $32.4 billion, with its median value being $32.6 billion (2022).
  • As far as peak fluctuations go, Gsk's Invested Capital plummeted by 3068.83% in 2022, and later soared by 9252.17% in 2023.
  • Over the past 5 years, Gsk's Invested Capital (Quarter) stood at $47.0 billion in 2021, then crashed by 30.69% to $32.6 billion in 2022, then skyrocketed by 92.52% to $62.8 billion in 2023, then grew by 1.9% to $64.0 billion in 2024, then plummeted by 97.19% to $1.8 billion in 2025.
  • Its Invested Capital was $1.8 billion in Q2 2025, compared to $64.0 billion in Q4 2024 and $62.8 billion in Q4 2023.